Loe patent for mozobil?

What is the patent landscape for Mozobil (plerixafor)?

Mozobil is the brand name for plerixafor, a drug used to mobilize hematopoietic stem cells before collection (commonly for autologous stem cell transplant). Patent coverage for a drug like Mozobil typically includes one or more patents on the active ingredient, formulations, and/or methods of use, and these can expire at different times depending on filing and prosecution history.

However, the exact “Loe patent” you’re asking for depends on which patent you mean (for example: the earliest priority patent, the last active US patent, or a specific listed patent in a patent register). With only “Loe patent for mozobil” in your question, the specific patent number, country (US vs. EU vs. other), and jurisdiction aren’t provided, so I can’t state a precise expiry date without those details.

Which country’s patent expiry date do you need?

Drug patent expiry is jurisdiction-specific. If you want the “last patent expiry” for Mozobil, you’ll need to specify:
- Country/region (most commonly US or EU/UK)
- Whether you mean “earliest priority,” “first commercial exclusivity end,” or “last composition/method patent end”

If you tell me the country and what you want to know (e.g., “last patent in the US” or “when can generics enter”), I can narrow it to the right set of patents.

How to identify the right patent for Mozobil (and avoid the common mix-ups)

Searchers often get different “expiry” dates depending on what they pull:
- Active ingredient patents vs. formulation patents (can expire separately)
- Method-of-use patents (can remain even after some composition claims end)
- Patent term adjustments and extensions (can change an expiration date)
- Patent status vs. marketing exclusivity (regulatory exclusivity can extend beyond some patent ends)

If you share a patent number or a link to the patent listing you’re looking at, I can help interpret what it covers and what the likely relevance is to generics.

If your goal is generics: can a generic enter right at patent expiry?

A generic’s ability to launch usually depends on more than one date:
- Whether any later-expiring patents still cover the drug or its use
- Whether regulatory exclusivities or data protection periods still apply
- Whether a generic can avoid infringement by design (label carve-outs, different methods, etc.)

If you tell me your target market (US/EU/etc.) and whether you mean “generic launch date,” I can map the logic to the correct type of exclusivity.

What I need from you to give a specific “Mozobil patent expiry” answer

Reply with any one of the following and I’ll take it from there:
- The country (US, EU, UK, etc.)
- The patent number (or a link to the listing)
- The wording of the patent claim category you mean (composition, formulation, method, or process)
- What you mean by “Loe” (for example, “LOE” as in “loss of exclusivity”)

Sources

I don’t have enough information from your prompt to cite specific Mozobil patent documents or an expiry date accurately.